The Food and Drug Administration has issued a warning to patients and healthcare providers about overdoses associated with a drug used for weight loss.
FDA officials said the agency has received reports of dosing errors associated with compounded semaglutide injectable products, resulting in patients seeking medical attention or requiring hospitalization after receiving between five and 20 times the intended dose.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.